| Submission to first decision
(The average time from manuscript submission to desk rejection, direct rejection/acceptance or assignment to the first editor) Note: For manuscripts that fully comply with the journal template. However, this timeframe does not apply to manuscripts with formatting or guideline deficiencies. If a manuscript is returned to the authors for corrections, the administrative review process will restart from the re-submission date. |
3 weeks |
|---|---|
| Submission to decision after review (For papers that are sent to review, the average time from submission to receipt of first editor decision) | 6 weeks |
| Submission to final decision (The average time from manuscript submission to the final editorial decision) | 16 weeks |
| Submission to publication (The average time from acceptance to publication. Manuscript published in early view are also included in this calculation) | 24 weeks |
ACTA Pharmaceutica Sciencia
2017 , Vol 55 , Num 3
Can Tissue Factor, A Multifactorial Molecule of the Hemostasis, be used As A Biomarker for Thrombosis, Inflammation and Cancer?
1 Division of Biochemistry Faculty of Medicine, Medipol University, Istanbul, TurkeyDOI : 10.23893/1307-2080.APS.05521 Viewed : 17864 - Downloaded : 6366 Tissue factor (TF) is a transmembrane protein found in many tissues and is active in various biological reactions. It is a member of the cytokine receptor superfamily and is referred to as CD 142 because of this feature. TF is also known as Factor III in the coagulation system and binds FVII/VIIa. The TF and FVIIa complex has both procoagulant and signaling activities. It functions in many biological processes, including hemostasis, thrombosis, inflammation and cancer. TF is essential for haemostasis but increased TF expression within atherosclerotic plaques and TF positive microparticles were detected in thrombotic conditions. TF increases inflammation by enhancing intravascular fibrin deposition and activates proteaseactivated receptors (PARs). TF and FVIIa complex also contribute to tumor growth by activating PAR2. Recent retrospective studies have shown that TF positive microparticles increase in the plasma of cancer patients. Therefore TF may be suggested to be used as a biomarker. However further studies are required to reveal the availability of TF as a biomarker to identify cancer and risk of thromosis and inflammation. Keywords : Tissue Factor, Hemostasis, Thrombosis, Inflammation, Cancer